- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on Nov 14, 2025)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| Nov 17, 2025 | T-2248-24 | M | Wolseley Canada Inc. V. Taps Depot Ltd. (Trade Mark) | Toronto | 1.1 d |
| Nov 17, 2025 | T-2055-25 | MSC | Niagara River Trading Company Inc. V. A & D Fiesta Inc. (unknown) | Ottawa | 3 h |
| Nov 17, 2025 | T-3922-25 | CMC | Astrazeneca Canada Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Olaparib*) | Toronto | 30 m |
| Nov 18, 2025 | T-4172-25 | M | Commissioner Of Competition V. Novartis Pharmaceuticals Canada Inc. Advanced (unknown) | Montréal | 1.5 h |
| Nov 18, 2025 | T-673-22 | TMC | Groupe Zoom Media Inc. V. Zoom Video Communications, Inc. (Trade Mark) | Ottawa | 1 h |
| Nov 19, 2025 | T-3386-24 | M | Aralez Pharmaceuticals Canada Inc. V. Laboratoire Riva Inc. Et Al. (Patent - Diclofenac*) | Toronto | 3 h |
| Nov 19, 2025 | T-3388-24 | M | Aralez Pharmaceuticals Canada Inc. V. Laboratoire Riva Inc. Et Al. (Patent - Diclofenac*) | Toronto | 3 h |
| Nov 19, 2025 | T-1420-18 | CMC | Ncs Multistage Inc. V. Kobold Corporation, Et Al (Patent) | Vancouver | 1 h |
| Nov 19, 2025 | T-567-20 | CMC | Ncs Multistage Inc. V. Promac Industries Ltd. (Patent) | Vancouver | 1 h |
| Nov 19, 2025 | T-2606-23 | APM | Impulse Downhole Solutions Ltd. V. Challenger Downhole Tools Inc. (Patent) | Ottawa | 2 h |
| Nov 21, 2025 | T-1723-25 | CMC | Lodestar Anstalt V. Usconnect, Llc (Trade Mark) | Toronto | 30 m |
| Nov 21, 2025 | T-1725-25 | CMC | Lodestar Anstalt V. Usconnect, Llc (Trade Mark) | Toronto | 30 m |
| Nov 21, 2025 | T-1726-25 | CMC | Lodestar Anstalt V. Usconnect, Llc (Trade Mark) | Toronto | 30 m |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Nov 24, 2025 | T-91-20 | University Of Saskatchewan Et Al. V. Newagco Inc. Et Al. (Patent) | Toronto | 8 d |
| Dec 8, 2025 | T-91-20 | University Of Saskatchewan Et Al. V. Newagco Inc. Et Al. (Patent) | Toronto | 2 d |
| Jan 7, 2026 | T-745-24 | Viiv Healthcare Company Et Al V. Sandoz Canada Inc. (Patent) | Toronto | 8 d |
| Jan 19, 2026 | T-2405-23 | Bailey Metal Products Limited V. Dcm Metal Corp. (Patent) | Toronto | 5 d |
| Jan 22, 2026 | T-745-24 | Viiv Healthcare Company Et Al V. Sandoz Canada Inc. (Patent) | Toronto | 2 d |
| Jan 28, 2026 | T-2405-23 | Bailey Metal Products Limited V. Dcm Metal Corp. (Patent) | Toronto | 1 d |
| Feb 2, 2026 | T-400-22 | Pharmascience Inc. V. Biogen Canada Inc. Et Al. (PMNOC - Section 8 - Fampridine*) | Ottawa | 4 d |
| Feb 9, 2026 | T-400-22 | Pharmascience Inc. V. Biogen Canada Inc. Et Al. (PMNOC - Section 8 - Fampridine*) | Ottawa | 4 d |
| Feb 17, 2026 | T-400-22 | Pharmascience Inc. V. Biogen Canada Inc. Et Al. (PMNOC - Section 8 - Fampridine*) | Ottawa | 2 d |
| Mar 2, 2026 | T-673-22 | Groupe Zoom Media Inc. V. Zoom Video Communications, Inc. (Trade Mark) | Toronto | 5 d |
| Mar 2, 2026 | T-1583-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | Toronto | 8 d |
| Mar 2, 2026 | T-1584-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | Toronto | 8 d |
| Mar 9, 2026 | T-1346-21 | Federation Of Asian Canadians Toronto V. Asialicious Holdings Inc. Et Al. (Trade Mark) | Toronto | 4 d |
| Mar 11, 2026 | T-673-22 | Groupe Zoom Media Inc. V. Zoom Video Communications, Inc. (Trade Mark) | Toronto | 2 d |
| Mar 16, 2026 | T-1321-24 | Lundbeck Canada Inc. Et Al. V. Jamp Pharma Corporation (Patent - Vortioxetine*) | Toronto | 8 d |
| Mar 16, 2026 | T-1583-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | Toronto | 2 d |
| Mar 16, 2026 | T-1584-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | Toronto | 2 d |
| Mar 18, 2026 | T-1346-21 | Federation Of Asian Canadians Toronto V. Asialicious Holdings Inc. Et Al. (Trade Mark) | Toronto | 1 d |
| Mar 23, 2026 | T-1662-24 | Eisai Limited And Eisai R&d Et Al. V. Dr. Reddy's Laboratories Ltd. (Patent - Lenvatinib*) | Toronto | 8 d |
| Mar 30, 2026 | T-1321-24 | Lundbeck Canada Inc. Et Al. V. Jamp Pharma Corporation (Patent - Vortioxetine*) | Toronto | 2 d |
| Apr 7, 2026 | T-1608-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation And Al (Patent - Diclofenac*) | Montréal | 7 d |
| Apr 7, 2026 | T-1387-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation Et Al. (Patent - Diclofenac*) | Montréal | 7 d |
| Apr 13, 2026 | T-521-23 | Jamp Pharma Corporation V. Xymogen Ip, Llc Et Al. (Trade Mark) | Montréal | 4 d |
| Apr 15, 2026 | T-1662-24 | Eisai Limited And Eisai R&d Et Al. V. Dr. Reddy's Laboratories Ltd. (Patent - Lenvatinib*) | Toronto | 2 d |
| Apr 20, 2026 | T-1387-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation Et Al. (Patent - Diclofenac*) | Toronto | 1 d |
| Apr 20, 2026 | T-521-23 | Jamp Pharma Corporation V. Xymogen Ip, Llc Et Al. (Trade Mark) | Montréal | 1 d |
| Apr 21, 2026 | T-1608-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation And Al (Patent - Diclofenac*) | Toronto | 4 d |
| Apr 28, 2026 | T-1608-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation And Al (Patent - Diclofenac*) | Montréal | 1 d |
| May 11, 2026 | T-2102-24 | Nuvo Pharmaceuticals V. Auro Pharma Inc. Et Al. (Patent - Naproxen*) | Toronto | 9 d |
| May 25, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 4 d |
| May 28, 2026 | T-2102-24 | Nuvo Pharmaceuticals V. Auro Pharma Inc. Et Al. (Patent - Naproxen*) | Toronto | 2 d |
| Jun 1, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Jun 8, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Jun 15, 2026 | T-2962-24 | Pfizer Canada Ulc Et Al. V. Taro Pharmaceuticals Inc. (Patent - Bosutinib*) | Toronto | 10 d |
| Aug 17, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 17, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 17, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Sep 8, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 4 d |
| Sep 14, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 4 d |
| Sep 14, 2026 | T-1567-24 | Justin Stitches Inc. V. Makers Holdings Inc. (Trade Mark) | Vancouver | 5 d |
| Sep 21, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 4 d |
| Sep 28, 2026 | T-75-25 | Boehringer Ingelheim(canada) Ltd. Et Al V.laboratoire Riva Inc (Patent - Empagliflozin*) | Toronto | 2 d |
| Oct 19, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Oct 19, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 10 d |
| Oct 26, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Nov 4, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 2 d |
| Nov 18, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 2 d |
| Nov 23, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 8 d |
| Nov 23, 2026 | T-887-25 | Boehringer Ingelheim (canada) Ltd Et Al V. Auro Pharma Inc (Patent - Empagliflozin*) | To be determined (TrialJA) | 13 d |
| Dec 7, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 2 d |
| Dec 17, 2026 | T-887-25 | Boehringer Ingelheim (canada) Ltd Et Al V. Auro Pharma Inc (Patent - Empagliflozin*) | To be determined (TrialJA) | 2 d |
| Feb 1, 2027 | T-1627-25 | Hoffmann-la Roche Limited Et Al. V. Shanghai Henlius Biotech, Inc. Et Al. (Patent - Pertuzumab*) | Toronto | 4 d |
| Feb 8, 2027 | T-1627-25 | Hoffmann-la Roche Limited Et Al. V. Shanghai Henlius Biotech, Inc. Et Al. (Patent - Pertuzumab*) | Toronto | 4 d |
| Feb 15, 2027 | T-377-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Isreal Pharmaceuticals (Patent - Naloxone*) | Toronto | 4 d |
| Feb 16, 2027 | T-1627-25 | Hoffmann-la Roche Limited Et Al. V. Shanghai Henlius Biotech, Inc. Et Al. (Patent - Pertuzumab*) | Toronto | 2 d |
| Feb 16, 2027 | T-1245-25 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 4 d |
| Feb 22, 2027 | T-377-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Isreal Pharmaceuticals (Patent - Naloxone*) | Toronto | 4 d |
| Feb 22, 2027 | T-1245-25 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 4 d |
| Mar 2, 2027 | T-377-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Isreal Pharmaceuticals (Patent - Naloxone*) | Toronto | 2 d |
| Mar 3, 2027 | T-1245-25 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | To be determined (TrialJA) | 2 d |
| Mar 10, 2027 | T-2504-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent) | To be determined (TrialJA) | 10 d |
| Mar 10, 2027 | T-2505-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent - Trametinib*) | To be determined (TrialJA) | 10 d |
| Mar 30, 2027 | T-2504-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent) | To be determined (TrialJA) | 2 d |
| Mar 30, 2027 | T-2505-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent - Trametinib*) | To be determined (TrialJA) | 2 d |
| Apr 5, 2027 | T-2529-25 | Nuvo Pharmaceuticals (ireland) Designated Activity Company V. Pharmascience (Patent - Naproxen*) | Toronto | 4 d |
| Apr 12, 2027 | T-2529-25 | Nuvo Pharmaceuticals (ireland) Designated Activity Company V. Pharmascience (Patent - Naproxen*) | Toronto | 4 d |
| Apr 19, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 4 d |
| Apr 21, 2027 | T-2529-25 | Nuvo Pharmaceuticals (ireland) Designated Activity Company V. Pharmascience (Patent - Naproxen*) | Toronto | 2 d |
| Apr 26, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 4 d |
| May 10, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 4 d |
| May 10, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 2 d |
| May 17, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 3 d |
| May 25, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 2 d |
| Sep 20, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 4 d |
| Sep 27, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 3 d |
| Oct 4, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 4 d |
| Oct 19, 2027 | T-704-25 | Genevant Sciences Gmbh Et Al. V. Moderna Biopharma Canada Corp Et Al. (Patent) | Toronto | 3 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Feb 18, 2026 | T-28-24 | Grc Food Services Ltd. V. Chocoladefabriken Lindt & Sprungli Ag | Trade Mark - Appeal of a decision of the Registrar | Vancouver | 1 d |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location |
| Oct 30, 2025 | A-3-24 | Re:sound V. Pandora Media, Llc Et Al. | S.28 Copyright Board | Toronto |
| Dec 15, 2025 | A-331-24 | Proslide Technology, Inc. V Whitewater West Industries, Ltd. | Appeal (S.27 - Final) - Patent Act [from T-1449-20 - Patent Infringement] | Ottawa |
| Dec 18, 2025 | A-403-24 | Therme Development (cy) Ltd. V. Auberge & Spa Le Nordik Inc. Et Al. | Appeal (S.27 - Final) - Trade-marks Act [from T-225-23 - Trade Mark Expungement] | Ottawa |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.